Cobitolimod Oligonucleotide Dosing for Ulcerative Colitis Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ulcerative colitis, such as glucocorticosteroids and TNF-α inhibitors, have limitations including side effects, temporary remission induction, and loss of response over time, necessitating the need for more effective and safer dosage regimes for cobitolimod, an immunomodulatory oligonucleotide targeting Toll-like receptor 9.
Innovation Solution
Administering cobitolimod at doses of 100 mg to 350 mg, preferably 125 mg, on at least four separate occasions, each a week apart, to maximize its efficacy and safety profile for treating inflammatory bowel diseases like ulcerative colitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticosteroids are used to treat active UC, then inflammation is reduced and symptoms are controlled, but long-term use causes significant side effects and may impair healthy anabolic processes
Solution Approach 1:
The patent changes the therapeutic parameter from glucocorticosteroids to cobitolimod (an oligonucleotide), fundamentally altering the mechanism of action while maintaining anti-inflammatory efficacy. This parameter change allows achieving the same therapeutic goal (inflammation control) without the harmful side effects associated with long-term glucocorticosteroid use
2Reliability
If TNF-α inhibitors are administered to induce remission, then clinical response is achieved, but response is lost over time and temporary remission only is obtained
Solution Approach 1:
The patent changes the therapeutic agent from TNF-α inhibitors to cobitolimod, a different class of drug (oligonucleotide) with a novel mechanism of action. This parameter change aims to achieve sustained remission by targeting a different pathway, potentially overcoming the tolerance and loss of response that occur with TNF-α inhibitors over time
3Reliability
If conventional drugs like 5-ASA are used to control mild UC, then disease is controlled in milder cases, but they are insufficient for moderate to severe attacks
Solution Approach 1:
The patent positions cobitolimod as a universal therapeutic agent that can effectively treat ulcerative colitis across all severity levels (mild, moderate, and severe), replacing the need for stepped-care approaches with multiple different drug classes. The oligonucleotide demonstrates broad adaptability to different disease severities while maintaining a consistent mechanism of action
Data Source
AI summary
The present invention provides an oligonucleotide comprising the sequence 5′-GGAACAGTTCGTCCATGGC-3′ (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 100 mg to 350 mg of said oligonucleotide are administered to the subject on at least four separate occasions, wherein the separate occasions are each a week apart.